RUBICON Rubicon Research Q1 FY27 results (Apr–Jun 2026) and concall
Rubicon Research Limited delivered a strong Q1 FY27, marked by significant year-on-year growth in revenue, EBITDA, and PAT, driven by a diversified product portfolio and strategic focus on specialty products. The company successfully navigated FDA inspections for its Pithampur and newly acquired New Jersey facilities, paving the way for future commercialization. Despite temporary cash flow impacts from delayed GST refunds and a strategic shedding of lower-margin USD business, management expressed confidence by revising its FY27 EBITDA guidance upwards, reflecting robust operational efficiency
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 51.7%, net profit up 97.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 296 | 313 | 358 | 352 | 412 +39% | 476 +52% | 514 +44% | 534 +52% |
| EBITDA | 62 | 70 | 72 | 79 | 94 +52% | 108 +54% | 119 +65% | 129 +63% |
| Net profit | 34 | 38 | 36 | 43 | 54 +59% | 73 +92% | 77 +114% | 85 +98% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
